StockData
Quest Diagnostics Inc logo

Quest Diagnostics Inc (DGX) stock

DGXNYSEServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Oct 23, 2026Score 12/300% above fair value
$251.82−1.10 (-0.43%)

Close on Oct 30, 2026Market cap $27.79BP/E 26.8Yield –

Earnings

Quest Diagnostics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 9, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$3.10B
+9.9% on a year earlier
adjusted diluted EPS, Q3 FY2026
$3.00
$2.60 a year earlier
Latest guidance
Raised
Oct 22, 2026 · 5 items

Quarterly results

Revenue and earnings per share from each of Quest Diagnostics's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 9, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Oct 22, 2026before the open$3.10B+9.9%$2.78$3.00Release
Q2 FY2026ended Jun 30, 2026Jul 23, 2026before the open$3.04B+10.1%$2.84$3.12Release
Q1 FY2026ended Mar 31, 2026Apr 21, 2026before the open$2.90B+9.4%$2.24$2.50Release
Q4 FY2025ended Dec 31, 2025Feb 10, 2026before the open$2.81B+7.3%$2.18$2.42Release
Q3 FY2025ended Sep 30, 2025Oct 21, 2025before the open$2.82B+13.3%$2.16$2.60Release
Q2 FY2025ended Jun 30, 2025Jul 22, 2025before the open$2.76B+15.0%$2.47$2.62Release
Q1 FY2025ended Mar 31, 2025Apr 22, 2025before the open$2.65B+11.8%$1.94$2.21Release
Q4 FY2024ended Dec 31, 2024Jan 30, 2025before the open$2.62B+14.4%$1.95$2.23Release
Q3 FY2024ended Sep 30, 2024Oct 22, 2024before the open$2.49B+8.3%$1.99$2.30Release
Q2 FY2024ended Jun 30, 2024Jul 23, 2024before the open$2.40B+2.6%$2.03$2.35Release
Q1 FY2024ended Mar 31, 2024Apr 23, 2024before the open$2.37B+1.7%$1.72$2.04Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Quest Diagnostics's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Net revenuesFY2026$11.95B – $12.05B$11.78B – $11.90BRaisedJul 23, 2026
Net revenues increaseFY2026+8.3% – +9.2%+6.8% – +7.8%RaisedJul 23, 2026
revenuesFY2026$12.07B – $12.11B$11.70B – $11.82BRaisedOct 22, 2026
reported diluted EPSGAAPFY2026$10.21 – $10.31$9.45 – $9.65RaisedOct 22, 2026
Reported diluted EPSGAAPFY2026$9.97 – $10.17$9.58 – $9.78RaisedJul 23, 2026
adjusted diluted EPSnon-GAAPFY2026$11.25 – $11.35$10.50 – $10.70RaisedOct 22, 2026
adjusted diluted EPSnon-GAAPFY2026$11.05 – $11.25$10.63 – $10.83RaisedJul 23, 2026
Capital expendituresFY2026$550.00M$550.00MReaffirmedOct 22, 2026
Capital expendituresFY2026$550.00M$550.00MReaffirmedJul 23, 2026
Cash provided by operationsFY2026$1.90B$1.75BRaisedOct 22, 2026
Cash provided by operationsFY2026$1.80B$1.75BRaisedJul 23, 2026
Operating marginsnon-GAAPFY202775 – 150–NewJan 12, 2026

Guidance vs results

The last range Quest Diagnostics gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Adjusted diluted EPS$9.76 – $9.84$9.85Σ4QAbove range
FY2025EPS (GAAP)$8.58 – $8.66$8.75Σ4QAbove range
FY2025Revenue$10.96B – $11.00B$11.04BΣ4QAbove range
FY2025Revenue growth+11% – +11.4%+11.74%Σ4QAbove range

Guidance history

Every forecast Quest Diagnostics put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Oct 22, 2026Capital expendituresFY2026$550.00MReaffirmed
Oct 22, 2026adjusted diluted EPSFY2026$11.25 – $11.35Raised
Oct 22, 2026reported diluted EPSFY2026$10.21 – $10.31Raised
Oct 22, 2026Cash provided by operationsFY2026$1.90BRaised
Oct 22, 2026revenuesFY2026$12.07B – $12.11BRaised
Jul 23, 2026Capital expendituresFY2026$550.00MReaffirmed
Jul 23, 2026adjusted diluted EPSFY2026$11.05 – $11.25Raised
Jul 23, 2026Reported diluted EPSFY2026$9.97 – $10.17Raised
Jul 23, 2026Cash provided by operationsFY2026$1.80BRaised
Jul 23, 2026Net revenues increaseFY2026+8.3% – +9.2%Raised
Jul 23, 2026Net revenuesFY2026$11.95B – $12.05BRaised
Apr 21, 2026Capital expendituresFY2026$550.00MNew
Apr 21, 2026Adjusted diluted EPSFY2026$10.63 – $10.83New
Apr 21, 2026Reported diluted EPSFY2026$9.58 – $9.78New
Apr 21, 2026Cash provided by operationsFY2026$1.75BNew
Apr 21, 2026Net revenues increaseFY2026+6.8% – +7.8%New
Apr 21, 2026Net revenuesFY2026$11.78B – $11.90BNew
Feb 10, 2026Capital expendituresFY2026$550.00MNew
Feb 10, 2026Adjusted diluted EPSFY2026$10.50 – $10.70New
Feb 10, 2026Reported diluted EPSFY2026$9.45 – $9.65New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Quest Diagnostics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Quest Diagnostics Reports Third Quarter 2026 Financial Results;
    Results
  2. Quest Diagnostics Reports Second Quarter 2026 Financial Results;
    Results
  3. Prices $500 Million of Senior Notes
    News
  4. Quest Diagnostics Reports First Quarter 2026 Financial Results;
    Results
  5. Quest Diagnostics Elects Timothy Wentworth, Former CEO of
    Update
  6. Quest Diagnostics Reports Fourth Quarter and Full Year 2025 Financial Results;
    Results
  7. Quest Diagnostics Increases Dividend 7.5% To $0.86 Per Quarter;
    Results
  8. PRESENTATION DATED JANUARY 12, 2026
    Results
  9. Quest Diagnostics Reports Third Quarter 2025 Financial Results;
    Results
  10. Quest Diagnostics Reports Second Quarter 2025 Financial Results;
    Results
  11. Quest Diagnostics Reports First Quarter 2025 Financial Results;
    Results
  12. Driving Sustainable Growth, Delivering Long-term Value
    Update
  13. Karthik Kuppusamy, PhD Senior Vice President, Clinical Solutions
    Update
  14. Improving Quality, Experiences, and Productivity
    Update
  15. Quest Diagnostics to Highlight Strategic Priorities
    Update